| Income Statement | 2025-06-30 | |||
|---|---|---|---|---|
| Research and development | 16,006 | |||
| General and administrative | 132,848 | |||
| Total operating expenses | 148,854 | |||
| Loss from operations | -148,854 | |||
| Other income | 0 | |||
| Non-cash interest expense on convertible notes | 18,282 | |||
| Interest expense on loan payable | 2,493 | |||
| Interest income | 1 | |||
| Accretion to redemption value on convertible notes | 0 | |||
| Total other income (expense), net | -20,774 | |||
| Loss before provision for income taxes | -169,628 | |||
| Provision for income taxes | 2,400 | |||
| Net loss | -172,028 | |||
| Basic loss per common share | -0.02 | |||
| Diluted loss per common share | -0.02 | |||
| Weighted average number of common shares outstanding - basic | 7,236,447 | |||
| Weighted average number of common shares outstanding - diluted | 7,236,447 | |||
Mosaic ImmunoEngineering Inc. (CPMV)
Mosaic ImmunoEngineering Inc. (CPMV)